Entero Healthcare Solutions Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,087 Cr +32.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
EH

Entero Healthcare Solutions Ltd

Q4 FY26Retailing

Entero Healthcare Solutions Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,910Cr
+42.6% YoY
+11.9% QoQ
Net profit
₹45Cr
+45.2% YoY
+32.4% QoQ
Margin
4.5%
+0.9 pp YoY
+0.5 pp QoQ
Price₹1,424
Market cap₹5.5K Cr
P/E46.3

The short version

Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions. Revenue growth guidance for FY '27 is approximately 23%, combining ~11% calendarization impact and ~12% organic growth.

From Entero Healthcare Solutions Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions.
  • Organic growth is expected to contribute significantly, with pharma and MedTech segments both equally driving growth.
  • The company anticipates gross margin expansion, driven by scale and playing a full commercial role in certain product lines.
  • They expect calendarization impacts of around 11% in revenue growth.
  • Outperformance versus industry growth is targeted at around 1.4x to 1.5x the Indian Pharmaceutical Market (IPM) growth rate.
  • The focus will be on profitable revenue growth, operational efficiencies, and higher-margin businesses while rationalizing low-margin segments.

2 more points from Entero Healthcare Solutions Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Entero Healthcare Solutions Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Focus is on consolidating and optimizing existing acquisitions rather than pursuing new ones.
  • Company aims to spend more time organically building and optimizing the business platform rather than chasing new acquisition targets.
  • Investment in working capital is largely in place as of Q4 FY26; incremental working capital needs will not be significant unless growth exceeds the guided 23%.

2 more points from Entero Healthcare Solutions Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Retailing

Ranked on what management guided this quarter

Guidance-ranked
1Rentomojo
Rev 1Mar 3
2V2 Retail
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Entero Healthcare Solutions Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Entero Healthcare Solutions Ltd said on order book & pipeline — free account, 30 seconds.

Entero Healthcare Solutions Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Entero Healthcare Solutions Ltd Q4 FY26 results — key figures

Entero Healthcare Solutions Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,9101,339+42.6%1,707+11.9%
Operating profit (EBITDA)8649+75.5%68+26.5%
Operating margin4.5%3.6%+0.9 pp4%+0.5 pp
Profit before tax5837+56.8%40+45%
Net profit (PAT)4531+45.2%34+32.4%
EPS (₹)6.445.90+9.2%6.35+1.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.1K Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Retailing this season

  • Intrasoft Technologies (Q4 FY26)

    Revenue from operations for the quarter ended Mar-26: ₹13,604.74 lakhs . Key investor presentation takeaways from Intrasoft Technologies's Q4 FY26 investor pres

  • Brand Concepts (Q4 FY26)

    Q4 FY26 Revenue from Operations: INR 90.42 Cr., up 25.0% YoY (Page 11) . Key investor presentation takeaways from Brand Concepts Ltd's Q4 FY26 investor presenta

  • Womancart (Q4 FY26)

    Revenue for H2FY26: ₹8,388.9 Lakhs, up 125.8% YoY (Page 10, 8) . Key investor presentation takeaways from Womancart's Q4 FY26 investor presentation — and how it

  • Avenue Supermarts (Q4 FY26)

    FY22: ₹30,353 Cr . Key investor presentation takeaways from Avenue Supermarts's Q4 FY26 investor presentation — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Entero Healthcare Solutions Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Entero Healthcare Solutions Ltd Q4 FY26 results?

Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions. Revenue growth guidance for FY '27 is approximately 23%, combining ~11% calendarization impact and ~12% organic growth.

What is Entero Healthcare Solutions Ltd share price analysis?

Entero Healthcare Solutions Ltd currently shows a neutral. The stock trades at a P/E of 46.3 with a market cap of ₹5,479 Cr. Investors should review the full earnings analysis for detailed insights.

Is Entero Healthcare Solutions Ltd planning capital expenditure?

Focus is on consolidating and optimizing existing acquisitions rather than pursuing new ones.

Keep Entero Healthcare Solutions Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.